Merck, 85111504-1VL, A673

Application
Tumourigenicity studies
Biochem/physiol Actions
Derived from a 15 year old female patient. The cells form colonies on soft agar and tumours in antithymocyte serum treated mice.

The cell line A673 was originally described in 1973 as derived from a rhabdomyosarcoma, however, more recent analysis of the cells using advanced diagnostic techniques determined the cells to have characteristics of Ewing sarcoma rather than rhabdomyosarcoma. See citations for more information about this tumour status.
Human Ewing sarcoma
STR-PCR Data: Amelogenin: X
CSF1PO: 11,12
D13S317: 8,13
D16S539: 11
D5S818: 11,12
D7S820: 10,12
THO1: 9.3
TPOX: 8
vWA: 15,18
Preparation Note
DMEM + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Split sub-confluent cultures (70-80%) 1:3 to 1:10, i.e., seeding at 1-3x10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO₂; 37 °C.
Other Notes
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to [email protected].
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.